Small-bowel mucosal transglutaminase 2-specific IgA deposits in coeliac disease without villous atrophy: A prospective and randomized clinical study

Kaukinen, Katri; Peräaho, Markku; Collin, Pekka; Partanen, Jukka; Woolley, N.; Kaartinen, Tanja; Nuutinen, Tuula; Halttunen, Tuula; Mäki, Markku; Korponay-Szabó, Ilma Rita

doi:10.1080/00365520510023422

Cited by 131 publications

(113 citation statements)

References 22 publications

Supporting

Mentioning

110

Contrasting

Order By: Relevance

“…8 As a logical consequence, although there is a general consensus on dietary treatment for symptomatic subjects with enteropathy, it is not so for potential cases (i.e., patients with positive CDassociated serology, but no enteropathy). 9 However, accumulating evidence suggests that celiac patients may suffer from gluten-sensitive symptoms even before villous atrophy has developed, [10][11][12][13] and an increased risk of osteoporosis has been reported also for this group of patients. 10 In a recent work, Bertini et al have examined a cohort of CD patients, before and after gluten free diet GDF, and healthy controls, by 1 H NMR metabolic profiling of their serum and urine samples.…”

Section: Introductionmentioning

confidence: 99%

Are Patients with Potential Celiac Disease Really Potential? The Answer of Metabonomics

et al. 2010

View full text Add to dashboard Cite

Celiac disease (CD) is an autoimmune disorder caused by a permanent sensitivity to gluten in genetically susceptible individuals. Accurate diagnosis of CD at an early stage and its treatment with a gluten-free diet (GFD) are important for optimum treatment and prognosis. Recently, by employing a noninvasive metabonomic approach, we have shown that CD has a well-defined metabonomic signature. Here we address potential CD patients, defined as subjects who do not have, and have never had, a jejunal biopsy consistent with clear CD, and yet have immunological abnormalities similar to those found in celiac patients. Sixty-one overt CD patients at diagnosis, 29 patients with potential CD, and 51 control subjects were examined by 1 H NMR of their serum and urine: out of 29 potential CD patients, 24 were classified as CD and 5 as control subjects. Potential CD largely shares the metabonomic signature of overt CD. Most metabolites found to be significantly different between control and CD subjects were also altered in potential CD. Our results demonstrate that metabolic alterations may precede the development of small intestinal villous atrophy and provide a further rationale for early institution of GFD in patients with potential CD, as recently suggested by prospective clinical studies.

show abstract

Section: Introductionmentioning

confidence: 99%

Are Patients with Potential Celiac Disease Really Potential? The Answer of Metabonomics

et al. 2010

View full text Add to dashboard Cite

show abstract

“…These deposits appear in the mucosa even before they are detectable in the periphery. 55,59,60 In IgA-deficient celiac disease patients, these mucosal autoantibody deposits appear in the IgM-class instead. 61 Autoantibodies associated with extraintestinal manifestations of celiac disease Interestingly, in some cases, autoantibodies against distinct selfmolecules in addition to TG2 have been reported to coincide with specific clinical manifestations of celiac disease.…”

Section: Intestinal Autoantibodiesmentioning

confidence: 99%

Antibodies in celiac disease: implications beyond diagnostics

et al. 2011

Self Cite

View full text Add to dashboard Cite

“…Notably, intestinal deposits of IgA antibodies targeting TG2 are present at all stages of CD, including early developing CD (Kaukinen et al, 2005) as well as late stage refractory CD (Salmi et al,2006) where patients may be seronegative. With regards to B cell activation and differentiation, the hapten carrier model proposed by Sollid et al (1997), although not formally demonstrated in vivo, appears to hold true, whereby gluten-specific T cells can provide help to TG-specific B cells.…”

Section: Pathogenesismentioning

confidence: 99%

“…Even patients with CD may not have gastrointestinal symptoms. In patients without overt gastrointestinal involvement (enteropathy), serum antibodies to TG2 may be absent (Kaukinen et al, 2005). Patients with extraintestinal manifestations typically 8 have antibodies primarily reacting with different TG isozymes, TG3 in DH and TG6 in patients with gluten ataxia (Sardy et al, 2002;.…”

Section: Diagnosis Of the Spectrum Of Gluten Related Diseasesmentioning

confidence: 99%

The Neuroimmunology of Gluten Intolerance

Hadjivassiliou

Sanders

Aeschlimann

2016

Neuro-Immuno-Gastroenterology

View full text Add to dashboard Cite

The term Gluten Related Disorders (GRD) denotes a spectrum of diverse immune mediated diseases triggered by the ingestion of gluten (protein found in wheat, barley and rye). Coeliac disease (CD) or gluten sensitive enteropathy is the most recognised and studied entity within GRD.Extraintestinal manifestations, are gaining recognition and are increasingly the subject of further studies as they may hold the key to unravelling the pathophysiology of GRD. Such manifestations include skin involvement in the form of dermatitis herpetiformis (DH) and neurological dysfunction (eg gluten ataxia and gluten neuropathy). Furthermore the recent concept of extraintestinal manifestations without enteropathy (termed Non-Coeliac Gluten Sensitivity-NCGS) has become accepted as part of the same spectrum. In this chapter we review the neurological manifestations in GRD, discuss recent advances in diagnosis, and possible pathophysiological mechanisms.

show abstract

Small-bowel mucosal transglutaminase 2-specific IgA deposits in coeliac disease without villous atrophy: A prospective and randomized clinical study

Abstract: Clinically pertinent coeliac disease exists despite normal small-bowel mucosal villous architecture. Mucosal transglutaminase 2-specific IgA deposits can be utilized in detecting such patients with genetic gluten intolerance.

Cited by 131 publications

References 22 publications

Are Patients with Potential Celiac Disease Really Potential? The Answer of Metabonomics

Are Patients with Potential Celiac Disease Really Potential? The Answer of Metabonomics

Antibodies in celiac disease: implications beyond diagnostics

The Neuroimmunology of Gluten Intolerance

Contact Info

Product

Resources

About